Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR L861Q

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2	osimertinib Sensitive: A2 - Guideline osimertinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR L861Q	Lung Non-Small Cell Squamous Cancer	EGFR L861Q	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B	EGFR inhibitor Sensitive: B - Late Trials EGFR inhibitor Sensitive : B
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3	afatinib Sensitive: C3 – Early Trials afatinib Sensitive : C3
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4	osimertinib Sensitive: C4 – Case Studies osimertinib Sensitive : C4
EGFR L861Q	Small Cell Lung Cancer	EGFR L861Q	Small Cell Lung Cancer	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4	gefitinib Sensitive: C4 – Case Studies gefitinib Sensitive : C4
EGFR L861Q	Lung Cancer	EGFR L861Q	Lung Cancer	pan-ErbB inhibitor Sensitive: D – Preclinical pan-ErbB inhibitor Sensitive : D	pan-ErbB inhibitor Sensitive: D – Preclinical pan-ErbB inhibitor Sensitive : D
EGFR L861Q	Esophageal Cancer	EGFR L861Q	Esophageal Cancer	erlotinib Resistant: D – Preclinical erlotinib Resistant : D	erlotinib Resistant: D – Preclinical erlotinib Resistant : D
EGFR L861Q	Esophageal Cancer	EGFR L861Q	Esophageal Cancer	cetuximab Resistant: D – Preclinical cetuximab Resistant : D	cetuximab Resistant: D – Preclinical cetuximab Resistant : D
EGFR L861Q	Esophageal Cancer	EGFR L861Q	Esophageal Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	icotinib Sensitive: D – Preclinical icotinib Sensitive : D	icotinib Sensitive: D – Preclinical icotinib Sensitive : D
EGFR L861Q	Lung Adenocarcinoma	EGFR L861Q	Lung Adenocarcinoma	dacomitinib Sensitive: D – Preclinical dacomitinib Sensitive : D	dacomitinib Sensitive: D – Preclinical dacomitinib Sensitive : D